Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized comparison of two nonmyeloablative conditioning regimens before allogeneic hematopoietic cell transplantation
NL-OMON32010Phase 2Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Feb 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fludarabine and antithymocyte globulin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML) and 6 more (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Incidence of grade II-IV acute graft-versus-host disease. Started Feb 2009; status: active, not recruiting.
02
Drugs
fludarabineantithymocyte globulin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)myeloproliferative disorder (MPD)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON32010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32010.